MORPHOSYS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 68.65 EUR | +0.88% |
|
+0.96% | +101.91% |
| Sales 2024 * | 123M 133M | Sales 2025 * | 325M 353M | Capitalization | 2.58B 2.8B |
|---|---|---|---|---|---|
| Net income 2024 * | -430M -466M | Net income 2025 * | -116M -126M | EV / Sales 2024 * | 21.8 x |
| Net Debt 2024 * | 89.28M 96.82M | Net cash position 2025 * | 94.69M 103M | EV / Sales 2025 * | 7.65 x |
| P/E ratio 2024 * |
-6.08
x | P/E ratio 2025 * |
-33
x | Employees | 464 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 17.23% |
More Fundamentals
* Assessed data
More news
Latest transcript on MorphoSys AG
More press releases
More news
| 1 day | +0.88% | ||
| 1 week | +0.96% | ||
| 1 month | +3.70% | ||
| 3 months | +4.81% | ||
| 6 months | +180.89% | ||
| Current year | +101.91% |
1 week
67.25
68.65
1 month
66.0069.75
Current year
29.7369.75
1 year
14.5269.75
3 years
11.8170.80
5 years
11.81146.30
10 years
11.81146.30
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 19-08-31 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 23-08-06 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 18-05-16 |
| Director/Board Member | 67 | 18-05-16 | |
Marc Cluzel
CHM | Chairman | 69 | 12-05-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.44% | 125 M€ | -.--% | ||
| 0.80% | 17 M€ | -.--% | - | |
| 0.11% | 2 M€ | -.--% | ||
| 0.02% | 746 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 68.65 | +0.88% | 151,588 |
| 24-05-30 | 68.05 | -0.15% | 55,971 |
| 24-05-29 | 68.15 | +0.44% | 115,081 |
| 24-05-28 | 67.85 | -0.37% | 59,944 |
| 24-05-27 | 68.1 | +0.15% | 31,116 |
Delayed Quote Xetra, May 31, 2024 at 11:35 am EDT
More quotes
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Calendar
2024-08-06
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
68.65
EUR
Average target price
58.71
EUR
Spread / Average Target
-14.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +101.91% | 2.8B | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- MOR Stock
